Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Stem Cells for Osteochondral Lesions of the Talus
NCT03905824Phase 3Unknown
- Sponsor
- Universidad de Chile
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in osteochondral lesion of the talus (OLT) (2 arms), sponsored by Universidad de Chile. Primary endpoints: Change on tissue reparation quality at 1 year, Change over time of general health status at 2 years and 3 more. Status: unknown.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
osteochondral lesion of the talus (OLT)
Beyond the preview
Go deeper on NCT03905824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905824.